Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
  • Patent number: 12157775
    Abstract: Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: December 3, 2024
    Assignee: Zymeworks BC Inc.
    Inventors: Grant Raymond Wickman, Gordon Yiu Kon Ng, Nina E. Weisser
  • Patent number: 12152054
    Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: November 26, 2024
    Assignee: Genentech, Inc.
    Inventors: Hui F. Liu, Brian David Kelley, Deanna E. Myers, Beth McCooey, Krista Marie Petty
  • Patent number: 12151004
    Abstract: The disclosure provides radiolabeled and/or cytotoxin labelled antibodies and methods and uses of these antibodies. In one embodiment, provided is a cytotoxic agent comprising an antibody that specifically binds a target disease cell surface receptor, a cytotoxin, and a radiolabel, wherein the cytotoxin is linked directly or indirectly to the antibody, and wherein the radiolabel comprises a radionuclide and optionally a scaffold, wherein the scaffold is directly or indirectly coupled to the antibody. Also provided are methods of preparing the cytotoxic agent and methods of treating disease using the cytotoxic agent.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: November 26, 2024
    Assignee: University of Saskatchewan
    Inventors: Humphrey Fonge, Clarence Ronald Geyer, Siddesh Vrushabendra swamy Hartimath
  • Patent number: 12150991
    Abstract: Pharmaceutical compositions of anti-TSLP-R antibodies, and uses thereof, are provided herein. The pharmaceutical compositions can comprise for example, an anti-TSLP-R antibody, or antigen-binding fragment thereof, a pharmaceutically acceptable buffer, an excipient, and a surfactant, or other compositions as provided for herein.
    Type: Grant
    Filed: November 7, 2023
    Date of Patent: November 26, 2024
    Assignee: UPSTREAM BIO, INC.
    Inventors: Parika Petaipimol, Robert Patrick Gearing, Bingquan Wang, Geng Li, Jeremy Guo
  • Patent number: 12144859
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: November 19, 2024
    Assignees: Institut National De La Santa Et De La Recherche Medicale (Inserm), Duke University, Assistance Publique-Hôpitaux De Paris (APHP)
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • Patent number: 12138313
    Abstract: This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.
    Type: Grant
    Filed: March 21, 2024
    Date of Patent: November 12, 2024
    Assignee: Bluefin Biomedicine, Inc.
    Inventors: Hong Ren, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Tinglei Gu
  • Patent number: 12139534
    Abstract: Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 12, 2024
    Assignee: BIOND BIOLOGICS LTD.
    Inventors: Motti Hakim, Dror Alishekevitz, Dana Haves Ziv, Edna Meilin, Yair Sapir, Avidor Shulman, Tehila Ben-Moshe, Ilana Mandel
  • Patent number: 12139764
    Abstract: Provided herein are compositions and methods for characterizing and treating cancer. In particular, provided herein are compositions and methods for identifying subjects with breast cancer with increased likelihood of bone metastasis and providing treatment to prevent such metastases.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: November 12, 2024
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Adam Watson-Hurthig, Ghassan Mouneimne, Casey Romanoski, Adam Grant, Megha Padi
  • Patent number: 12140592
    Abstract: The present invention includes methods, systems, and kits, for identifying and modifying the treatment of a systemic lupus erythematosus (SLE) patient prior to the presence of autoantibodies, comprising: (a) obtaining a dataset representing protein expression level values for cytokines and molecules; (b) assessing the dataset for protein expression levels of at least one innate serum mediator; (c) assessing the dataset for protein expression levels of at least one adaptive serum mediator; and (d) determining the likelihood that the patient will develop SLE prior to the onset of autoantibodies when compared to a control.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 12, 2024
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Judith Ann James, Melissa Elizabeth Munroe
  • Patent number: 12129308
    Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: October 29, 2024
    Assignees: MERCK PATENT GMBH, ABLYNX NV
    Inventors: Francis Descamps, Gerald Beste, Guy Hermans, Hans Guehring, Lars Toleikis, Christoph Ladel
  • Patent number: 12128103
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: April 16, 2024
    Date of Patent: October 29, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Patent number: 12115192
    Abstract: Disclosed herein are chimeric antigen receptors (CARs) that target MUC1*. In some embodiments, the CARs have been optimized to reduce T cell exhaustion.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: October 15, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Patent number: 12110335
    Abstract: This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: October 8, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Michael Benz, Remko Alexander Bakker, Holger Fuchs, Fei Han, Sandeep Kumar, Sarah Low, Justin M. Scheer, Leo Thomas
  • Patent number: 12098204
    Abstract: The present invention relates to a humanized anti-human PD-L1 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human PD-L1 monoclonal antibody provided in the present invention has high affinity and specificity for PD-L1, stimulates T cells to secrete cytokines, and specifically relieves the negative immune regulation by PD-L1. The effect of this antibody is not achieved by directly blocking the interaction between PD-1 and PD-L1, presenting a new mechanism of immune checkpoint regulation. Therefore, the functional humanized anti-human PD-L1 monoclonal antibody provided in the present invention activates T cells by regulating the PD-L1 signaling pathway, thereby achieving the purpose of tumor immunotherapy.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 24, 2024
    Assignee: Nanjing Genscript Biotech Co., Ltd.
    Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yanling Mi, Chunchen Wu
  • Patent number: 12098207
    Abstract: The present invention provides methods for treating, preventing or ameliorating a neutrophilic dermatosis. The methods of the present invention include administering to a patient suffering from a neutrophilic dermatosis a pharmaceutical composition including an anti-interleukin-36 receptor (anti-IL-36R) antibody.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: September 24, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jay Fine, Janine Lamar, Steven John Padula, Meera Ramanujam, Sudha Visvanathan
  • Patent number: 12098203
    Abstract: This invention relates to a hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively, and wherein one of said variable domain pairs is specific for human serum albumin and the other said variable domain pair is specific for human CD3.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 24, 2024
    Assignee: Numab Therapeutics AG
    Inventors: David Urech, Tea Gunde, Sebastian Meyer, Christian Hess, Alexandre Simonin
  • Patent number: 12084489
    Abstract: Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: September 10, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Masaru Kanekiyo, Michael Gordon Joyce, Wei Bu, Jeffrey I. Cohen, Yaroslav Tsybovsky
  • Patent number: 12084501
    Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3?, polynucleotides encoding them, vectors, host cells, methods of making and using them.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: September 10, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Adam Zwolak, Raymond Brittingham, Scott R. Brodeur, Rajkumar Ganesan, Sherry Lynn La Porte, Jinquan Luo, Fang Yi, Colleen M. Kane, Triveni K. Bhatt
  • Patent number: 12084491
    Abstract: The invention provides a method of treating, preventing or ameliorating Parkinson's disease with Prasinezumab.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: September 10, 2024
    Assignees: Prothena Biosciences Limited, F. Hoffmann-La Roche, Inc.
    Inventors: Gennaro Pagano, Wagner Zago
  • Patent number: 12077579
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: September 3, 2024
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim
  • Patent number: 12076399
    Abstract: Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: September 3, 2024
    Assignee: Cothera Bioscience, Inc.
    Inventors: Yihong Zhang, Wang Wei, Yiyou Chen
  • Patent number: 12071622
    Abstract: The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.
    Type: Grant
    Filed: January 4, 2023
    Date of Patent: August 27, 2024
    Assignee: Institute For Cancer Research
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • Patent number: 12060423
    Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: August 13, 2024
    Assignee: Forty Seven, Inc.
    Inventors: Marie Châlons-Cottavoz, Mehdi Lahmar, Klaus Schwamborn, Nicola Beltraminelli, Stéphanie Fallot, Pierre Garrone
  • Patent number: 12060411
    Abstract: This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: August 13, 2024
    Assignee: The Rockefeller University
    Inventors: Michel Nussenzweig, Zijun Wang
  • Patent number: 12060419
    Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express CD79A.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: August 13, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kevin Friedman, Molly Reed Perkins
  • Patent number: 12060431
    Abstract: The present invention relates to a CD20 binding antibody which is capable of depleting B cells, and a BLyS binding antibody which is capable of antagonizing BLyS, as a combination for use in the treatment of an autoimmune disorder. The invention also relates to dosages, duration of treatment and time lapses between administration of the CD20 binding antibody which is capable of depleting B cells, and the BLyS binding antibody which is capable of antagonizing BLyS.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: August 13, 2024
    Assignees: GlaxoSmithKline Intellectual Property Management Limited, GlaxoSmithKline Intellectual Property Limited
    Inventor: Robert B. Henderson
  • Patent number: 12054544
    Abstract: The present invention relates to pharmaceutical compositions containing a combination of a first antigen-binding molecule and a second antigen-binding molecule, wherein the first antigen-binding molecule and the second antigen-binding molecule are not linked by a covalent bond, and they are more likely to form a heterodimer than homodimers when mixed in solution. Furthermore, the present invention relates to antigen-binding molecules, therapeutic methods, and screening methods that are associated with the combination.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 6, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hitoshi Katada, Takeaki Kawai
  • Patent number: 12054774
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: August 6, 2024
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer
  • Patent number: 12049517
    Abstract: This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: July 30, 2024
    Assignee: Ab Studio Inc.
    Inventors: Yue Liu, Wenyan Cai, Jiadong Shi
  • Patent number: 12042491
    Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain from 10 mg/ml to 100 mg/ml of a cinchona alkaloid or a quinolone compound, e.g. chloroquine or hydroxychloroquine, a solvent that is at least one of a glycerin, a propylene glycol (PG), and a polyethylene glycol (PEG); and a carbonate. In such formulations, the solvent and the carbonate are present in amounts sufficient to promote resistance to hydrogen peroxide mediated degradation of the cinchona alkaloid or quinoline.
    Type: Grant
    Filed: December 30, 2022
    Date of Patent: July 23, 2024
    Assignee: TaP Pharmaceuticals AG
    Inventors: Nilesh Parikh, William Hite
  • Patent number: 12037398
    Abstract: The invention relates to anti-VLA-4 antibodies and binding fragments thereof. The invention further includes polynucleotides encoding said antibodies and binding fragments thereof and methods of manufacturing said antibodies and binding fragments thereof. The invention further includes methods of treating patients suffering from multiple sclerosis and/or epilepsy by administration of said antibodies and binding fragments thereof. The invention further includes methods of reducing the susceptibility to scrambling of a recombinant anti-alpha 4 antibody or a binding fragment thereof.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 16, 2024
    Assignee: Biogen MA Inc.
    Inventors: Janine Lisa Ferrant-Orgettas, Robert Blake Pepinsky, Ellen Duggan Cahir-McFarland, Nadia Giselle D'Lima, Joseph Walter Arndt, Karl John Mortley Hanf, Thomas Owen Cameron, Ellen Garber Stark
  • Patent number: 12037404
    Abstract: The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vector are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: July 16, 2024
    Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Nancy Yuk-Yu Ip, Kit Yu Fu, Wing Yu Fu, Dimiter S. Dimitrov, Tianlei Ying
  • Patent number: 12037646
    Abstract: A function of cyclin-dependent kinase 12 (CDK12) as a biomarker for a human epidermal growth factor receptor 2 (HER2)-positive cancer and anti-HER2 therapy, and a use of the CDK12 are provided. The CDK12 may be used for companion diagnostics of a HER2-targeted therapeutic agent for a subject having HER2+ cancer as a prognostic factor and a predictive factor for response of the subject to the anti-HER2-targeted therapeutic agent in HER2+ cancer, or used to check the probability of expressing resistance to the HER2-targeted therapeutic agent. When the CDK12 is amplified or expressed at a level higher than a reference value, the CDK12 may be suppressed to overcome the resistance to the HER2 therapeutic agent and improve a therapeutic effect, thereby improving the therapeutic efficiency of HER2-positive cancer.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: July 16, 2024
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Gu Kong, Jeong Yeon Lee, Hee-Joo Choi, Ha Ni Jo
  • Patent number: 12036204
    Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: July 16, 2024
    Assignees: EISAI R&D MANAGEMENT CO., LTD., ONO PHARMACEUTICAL CO., LTD.
    Inventors: Taro Semba, Yasuhiro Funahashi, Takuya Suzuki
  • Patent number: 12037380
    Abstract: Provided are proteins comprising a variant IgG Fc region, wherein the proteins exhibit significantly reduced binding to human Fc?RI when compared with a reference protein comprising the amino acid substitutions L234A/L235A/P329G. Also provided are compositions, methods of treatment and methods to reduce Fc-induced effector functions in a parent protein.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: July 16, 2024
    Assignee: MABSOL VE LIMITED
    Inventors: Geoffrey Hale, Ian Wilkinson
  • Patent number: 12030948
    Abstract: The present invention discloses a stable pharmaceutical formulation of an antibody, wherein the formulation contains buffer, surfactant, sugar, and optionally contains a free amino acid. The disclosed formulation is stable at 50° C. for two weeks. In addition, the formulation maintains at least 96% of the antibody in monomeric form under above said storage conditions.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: July 9, 2024
    Assignee: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Murali Jayaraman, Anuja Chandrasekar
  • Patent number: 12011481
    Abstract: The instant disclosure provides antibodies that specifically bind to TIM 3 and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: June 18, 2024
    Assignee: AGENUS INC.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
  • Patent number: 12006371
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: June 11, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Patent number: 11999781
    Abstract: The present invention relates to antibodies which bind to TNF? and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 4, 2024
    Assignee: Tillotts Pharma AG
    Inventors: Esther Maria Furrer, Stian Foss, Jan Terje Andersen, Inger Sandlie
  • Patent number: 11999790
    Abstract: This disclosure relates to anti-human OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: June 4, 2024
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni
  • Patent number: 11993642
    Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: May 28, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
  • Patent number: 11992529
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 28, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Patent number: 11987640
    Abstract: Mesothelin (MSLN) is expressed on pancreatic cancers, ovarian cancers and mesotheliomas. The present disclosure provides antigen-binding molecules, including anti-MSLN antibodies, and bispecific antigen-binding molecules that bind to both MSLN and a T cell antigen (e.g., CD3) and activate T cells in the presence of MSLN-expressing tumor cells. The antigen-binding molecules of this disclosure are useful for the treatment of diseases and disorders in which a MSLN-targeted immune response is desired and/or therapeutically beneficial. For example, the antigen-binding molecules of the present disclosure are useful for the treatment of various cancers, including pancreatic cancer, ovarian cancer and mesotheliomas.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: May 21, 2024
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Colin Correnti, Ashok Bandaranayake, Christopher Mehlin, James M. Olson, Soheil Meshinchi
  • Patent number: 11987633
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3? (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: May 21, 2024
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
  • Patent number: 11986530
    Abstract: Provided is a curcumin pharmaceutical preparation that is highly water soluble, can maintain the concentration of free curcumin in the blood sufficiently high by being administered parenterally, can effectively obtain a pharmacological action of curcumin, and is highly safe. A pharmaceutical composition for parenteral administration, including a water-soluble substance conjugate of curcumin as an active component.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: May 21, 2024
    Assignees: THERABIOPHARMA INC., KYOTO UNIVERSITY
    Inventors: Hideaki Kakeya, Masashi Kanai, Nobuaki Takahashi, Tadashi Hashimoto, Atsushi Imaizumi, Hitomi Ozawa
  • Patent number: 11986488
    Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: May 21, 2024
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Idit Shachar, Hadas Lewinsky, Lihi Radomir, Anna Wiener
  • Patent number: 11976131
    Abstract: The present application relates to humanized and/or deimmunized antibodies, antibody fragments or antibody derivatives that bind to Prostate Specific Membrane Antigen (PSMA) and methods for using said antibodies, antibody fragments or antibody derivatives in the treatment of prostate cancer and other neoplastic as well as neurological diseases.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 7, 2024
    Assignee: Heidelberg Pharma Research GmbH
    Inventors: Torsten Hechler, Andreas Pahl
  • Patent number: 11976136
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: May 7, 2024
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
  • Patent number: 11970533
    Abstract: Antibodies binding to human claudin 18.2 (CLDN 18.2) and bispecific antibodies binding to both human CLDN 18.2 and PD-L1, pharmaceutical compositions comprising such, and methods of using such for treating target diseases including cancer.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: April 30, 2024
    Assignee: SPARX BIOSCIENCE LIMITED
    Inventors: Guidong Zhu, Jingdong Ye, Jichun Ma, Jingdong Qin, Hongyu Zhao
  • Patent number: 11970544
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: April 30, 2024
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren